Fatty acid oxidation in the reperfused ischemic heart

American Journal of the Medical Sciences

Volumn 318, Issue 1, 1999, Pages 3-14

  Kantor, Paul F ^a   Dyck, Jason R B ^a   Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Carnitine palmitoyltransferase 1; Glucose oxidation; Malonyl coenzyme A; Pyruvate dehydrogenase; Trimetazidine

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; DICHLOROACETIC ACID; ENZYME INHIBITOR; ETOMOXIR; FATTY ACID; GLUCOSE; GLUCOSE INSULIN POTASSIUM SOLUTION; INSULIN; MALONYL COENZYME A; METHYLPALMOXYRATE; NICOTINIC ACID; OXFENICINE; POTASSIUM; PROPIONYLCARNITINE; PYRUVATE DEHYDROGENASE COMPLEX; RANOLAZINE; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ANGINA PECTORIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENERGY METABOLISM; ENZYME REGULATION; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; NONHUMAN; STUNNED HEART MUSCLE;

EID: 0033512660     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40566-X     Document Type: Conference Paper

References (101)

1. Taegtmeyer H. Carbohydrate interconversions and energy production. Circulation 1985;72(suppl. IV):1-8.
2. Neely JR, Morgan HE. Relationship between carbohydrate metabolism and energy balance of heart muscle. Annu Rev Physiol 1974;36:413-59.
3. Saddik M, Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 1991;266:8162-70.
4. Saddik M, Gamble J, Witters LA, et al. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 1993;268:25836-45.
5. Lopaschuk GD, Belke DD, Gamble J, et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994;1213:263-76.
6. Stanley WC, Lopaschuk GD, Hall JL, et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Cardiovasc Res 1997;33:243-57.
7. Friedrich J, Nascimben L, Liao R, et al Phosphocreatine T1 measurements with and without exchange in the heart. Magn Reson Med 1993;30:45-50.
8. Randle PJ, Hales CN, Garland PB, et al. The glucose fatty-acid cycle. It's role in insulin sensitivity and the metabolic disturbances of diabetic mellitus. Lancet 1963;1: 785-9.
9. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 1964; 93:652-65.
10. Garland PB, Randle PJ. Regulation of glucose uptake by muscles. 10. Effects of alloxan-diabetes, starvation, hypophysectomy and adrenalectomy, and of fatty acids, ketone bodies and pyruvate, on the glycerol output and concentrations of free fatty acids, long-chain fatty acyl-coenzyme A, glycerol phosphate and citrate-cycle intermediates in rat heart and diaphragm muscles. Biochem J 1964;93:678-87.
11. Kunau WH, Dommes V, Schulz H. β-Oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Prog Lipid Res 1995;34:267-342.
12. Lopaschuk GD. Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia. Am J Cardiol 1997;80:11A-6A.
13. Van der Vusse GJ, Glatz JF, Stam HC, et al. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992;72:881-940.
14. McGarry JD, Leatherman GF, Foster DW. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J Biol Chem 1978;253:4128-36.
15. McGarry JD, Woeltje KF, Kuwajima M, et al. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes 1989;5:271-84.
16. Kudo N, Barr AJ, Barr RL, et al. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995;270:17513-20.
17. Brown NF, Weis BC, Husti JE, et al. Mitochondrial carnitine palmitoryltransferase I isoform switching in the developing rat heart. J Biol Chem 1995;270:8952-7.
18. Esser V, Brown NF, Cowan AT, et al. Expression of a cDNA isolated from rat brown adipose tissue and heart identifies the product as the muscle isoform of carnitine palmitoyltransferase I (M-CPT I). M-CPT I is the predominant CPT I isoform expressed in both white (epididymal) and brown adipocytes. J Biol Chem 1996;271:6972-7.
19. Weis BC, Esser V, Foster DW, et al. Rat heart expresses two forms of mitochondrial carnitine palmitoyltransferase I. The minor component is identical to the liver enzyme. J Biol Chem 1994;269:18712-5.
20. Cook GA, Lappi MD. Carnitine palmitoyltransferase in the heart is controlled by a different mechanism than the hepatic enzyme. Mol Cell Biochem 1992;116:39-45.
21. McGarry JD, Mills SE, Long CS, et al. Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Biochem J 1983;214:21-8.
22. Saggerson ED, Carpenter CA. Effects of fasting, adrenal-ectomy and streptozotocin-diabetes on sensitivity of hepatic carnitine acyltransferase to malonyl CoA. FEBS 1981;129: 225-8.
23. i values for malonyl CoA. J Biol Chem 1987;262:2050-5.
24. Kudo N, Gillespie JG, Kung L, et al. Characterization of 5′-AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1996;1301:67-75.
25. Lopaschuk G, Witters LA, Itoi T, et al. Acetyl-CoA carboxylase involvement in the rapid maturation of fatty acid oxidation in the newborn rabbit heart. J Biol Chem 1994; 269:25871-8.
26. Weiss RG, Bottomley PA, Hardy CJ, et al. Regional high energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 1990;323:1593-600.
27. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 1980;49:395-420.
28. Bianchi A, Evans JL, Iverson AJ, et al. Identification of an isozymic form of acetyl-CoA carboxylase. J Biol Chem 1990;265:1502-9.
29. Thampy GK. Identification and purification of an isozyme of acetyl-Coenzyme A carboxylase from rat heart. J Biol Chem 1989;264:17631-4.
30. Kim KH, Lopez-Casillas F, Bai DH, et al. Role of reversible phosphorylation of acetyl-CoA carboxylase in long-chain fatty acid synthesis. FASEB J 1989;3:2250-6.
31. Ha J, Daniel S, Broyles SAS, et al. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem 1994;269:22162-8.
32. Hardie DG. Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase. Biochim Biophys Acta 1992;1123:231-8.
33. Hardie DG, Carling D. The AMP-activated protein kinase. Fuel gauge of the mammalian cell? Eur J Biochem 1997;246: 259-73.
34. Verhoeven AJM, Woods A, Brennan CH, et al. The AMP-activated protein kinase gene is highly expressed in rat skeletal muscle. Eur J Biochem 1995;228:236-43.
35. Gao G, Widmer J, Stapleton D, et al. Catalytic subunits of the porcine and rat 5′-AMP-activated protein kinase are members of the SNF1 protein kinase family. Biochim Biophys Acta 1995;1266:73-82.
36. Carling D, Aguan K, Woods A, et al. Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism. J Biol Chem 1994;269:11442-8.
37. Gao G, Fernandez CS, Stapleton D, et al. Non-catalytic β- and γ-subunit isoforms of the 5′-AMP-activated protein kinase. J Biol Chem 1996;271:8675-81.
38. Dyck JRB, Gao G, Widmer J, et al. Regulation of 5′-AMP-activated protein kinase activity by noncatalytic β and γ subunits. J Biol Chem 1996;271:17798-803.
39. Hawley SA, Davison M, Woods A, et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 1996;271:27879-87.
40. Winz R, Hess D, Aebersold R, et al. Unique structural features and differential phosphorylation of the 280-kDa component (isozyme) of rat liver acetyl-CoA carboxylase. J Biol Chem 1994;269:14438-45.
41. Winder WW, Wilson HA, Hardie DG, et al. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J Appl Physiol 1997; 82:219-25.
42. Dyck JRB, Barr AJ, Barr RL, et al. Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation. Am J Physiol 1998;275: H2122-9.
43. Kolattukudy PE, Poulose AJ, Kim Y. Malonyl-CoA decarboxylase from avian, mammalian, and microbial sources. Methods-Enzymol 1981;71:150-63.
44. Schaefer S, Schwartz GG, Wisneski JA, et al. Response of high-energy phosphates and lactate release during prolonged regional ischemia in vivo. Circulation 1992;85:342-9.
45. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Ann Rev Med 1991;42:225-46.
46. Bunger R, Mallet RT, Hartman DA. Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart. Eur J Biochem 1989; 180:221-33.
47. Hunger R, Swindall B, Brodie D, et al. Pyruvate attenuation of hypoxia damage in isolated working guinea-pig heart. J Mol Cell Cardiol 1986;18:423-38.
48. Liu B, Clanachan AS, Schulz R, et al. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 1996;79:940-8.
49. 02 during reperfusion of ischemic hearts. Am J Physiol 1996;270:H72-H80.
50. Saddik M, Lopaschuk GD. Myocardial triglyceride turnover during reperfusion of isolated rat hearts subjected to a transient period of global ischemia. J Biol Chem 1991;267: 3825-31.
51. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 1993;264:135-44.
52. Gjesdal K. Platelet function and plasma free fatty acids during acute myocardial infarction and severe angina pectoris. Scand J Haematol 1976;17:205-12.
53. Dennis SC, Gewers W, Opie LH. Protons in ischemia. Where do they come from; where do they go to? J Mol Cell Cardiol 1991;23:1077-86.
54. Kudo N, Kung L, Witters LA, et al. Heart contains an active 5′-AMP-activated protein kinase that is involved in the regulation of fatty acid oxidation [abstract]. Circulation 1994;92:I-771.
55. Ferrari R, Ceconi C, Curello S, et al. Left ventricular dysfunction due to the new ischemic outcomes: stunning and hibernation. J Cardiovasc Pharmacol 1996;28:S18-S26.
56. Vaughan-Jones RD, Eisner DA, Lederer WJ. Effects of changes of intracellular pH on contraction in sheep cardiac Purkinje fibres. J Gen Physiol 1987;89:1015-32.
57. Poole-Wilson PA. Regulation of intracellular pH in the myocardium-relevance to pathology. Mol Cell Biochem 1989; 89:151-5.
58. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-9.
59. Bagger JP, Nielsen TT, Henningsen P. Myocardial exchange of metabolites after nitroglycerin in patients with coronary artery disease. Int J Cardiol 1984;5:599-612.
60. Bagger JP, Nielsen TT, Thomassen A. Reproducibility of coronary haemodynamics and cardiac metabolism during pacing-induced angina pectoris. Clin Physiol 1985;5:359-70.
61. Rousseau MF, Hanet C, Pardonge-Lavenne E, et al. Changes in myocardial metabolism during therapy in patients with chronic stable angina: a comparison of long-term dosing with propranolol and nicardipine. Circulation 1986; 73:1270-80.
62. Rosano GM, Kaski JC, Arie S, et al. Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism. Eur Heart J 1996;17:1175-80.
63. Nagayama M, Fujita Y, Kanai T, et al. Changes in myocardial lactate metabolism during ramp exercise in patients with effort angina and microvascular angina. Jpn Circ J 1996;60:876-88.
64. Schelbert HR. Cardiac PET: microcirculation and substrate transport in normal and diseased human myocar-dium. Ann Nucl Med 1994;8:91-100.
65. Fragasso G, Chierchia SL, Rossetti E, et al. Abnormal myocardial glucose handling in patients with syndrome X: effect of beta-adrenergic blockade. G Ital Cardiol 1997;27: 1113-20.
66. Tateno M Tamaki N Yukihiro M, et al. Assessment of fatty acid uptake in ischemic heart disease without myocardial infarction. J Nucl Med 1996;37:1981-5.
67. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72(suppl V): V123-7.
68. Heusch G, Schulz R. Endogenous protective mechanisms in myocardial ischemia: hibernation and ischemic preconditioning. Am J Cardiol 1997;80:26A-33A.
69. Uren NG, Camici PG. Hibernation and myocardial ischemia: clinical detection by positron emission tomography. Cardiovasc Drugs Ther 1992;6:273-9.
70. Keller AM, Cannon PJ. Effect of graded reductions of coronary pressure and flow on myocardial metabolism and performance: a model of "hibernating" myocardium J Am Coll Cardiol 1991;17:1661-70.
71. Mai MT, Haaparanta MT, Luotolahti PN, et al. Fatty acid uptake is preserved in chronically dysfunctional but viable myocardium. Am J Physiol 1997;273:H2473-80.
72. Allison SP, Chamberlain MJ, Hinton P. Intravenous glucose tolerance, insulin, glucose and free fatty acid levels after myocardial infarction. Br Med J 1969;4:776-8.
73. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for the treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.
74. Brown WV. Review of clinical trials proving the hpid hypothesis. Eur Heart J 1990; 11(Suppl H):15-20.
75. Datta S, Das DK, Engelman RM, et al. Enhanced myocardial protection by nicotinic acid, an antilipolytic compound: mechanism of action. Basic Res Cardiol 1989;84:63-76.
76. Teo KK, Yusuf S, Furberg D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95.
77. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the post infarction period. Am J Cardiol 1997;80:35J-39J.
78. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism 1989;38:1124-44.
79. Khales H, Hellige G, Hunneman DH, et al. Influence of myocardial substrate utilization on the oxygen consumption of the heart. Clin Cardiol 1982;5:286-93.
80. Racey-Burns LA, Burns AH, Summer WR, et al. The effects of dichloroacetate on the isolated no flow arrested rat heart. Life Sci 1989;44:2015-23.
81. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990;29:H1079-85.
82. Wargovich TJ, MacDonald RG, Hill JA, et al. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 1988;61:65-70.
83. Bersin RM, Wolfe C, Kwasman N, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994;23:1617-24.
84. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994;37:279-88.
85. Cocco G, Rosseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992;20:131-8.
86. McCormack JG, Barr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normaxic, ischemic and reperfused ischemic rat hearts. Circulation 1996;93:135-42.
87. Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 1996;28:341-50.
88. Birand A, Kudaiberdieva GZ, Batyralieu TA, et al. Effects of Trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology 1997;48:413-22.
89. Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994;26:949-58.
90. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart [abstract]. J Mol Cell Cardiol 1998;30:A112.
91. Schwartz GG, Greyson C, Wisneski JA, et al. Inhibition of fatty acid metabolism alters myocardial high energy phosphates in vivo. Am J Physiol 1994;267:H224-31.
92. Meehan AG, Higgins AJ. Oleate plus oxfenicine improves functional recovery assessed via an intraventricular balloon, in ischemic reperfused rat hearts. Ann N Y Acad Sci 1994; 723:343-4.
93. Rupp H, Schulze, Vetter R. Dietary medium chain triglycerides can prevent changes in myosin and SR due to CPT 1 inhibition by etomoxir. Am J Physiol 1995;269:R630-40.
94. Lopaschuk GD, Wall SR, Olley PM, et al. Etomoxir, a carnitine palmitoyltranferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988;63:1036-43.
95. Schonekess BO, Allard MF, Lopaschuk GD. PropionylL-carnitine improvement of hypertrophied heart is accompanied by an increase in carbohydrate oxidation. Circ Res 1995;77:726-34.
96. Russell RR, Mommessin JI, Taegtmeyer H. Propionyl-L carnitine-mediated improvement in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol 1995;268: H441-7.
97. Ferrari R, Anard I. Utilization of propionyl-L-carnitine for the treatment of heart failure. In: De Jong JW, Ferrari R, editors. The carnitine system: a new therapeutical approach to cardiovascular diseases. Dordrecht (The Netherlands): Kluwer Academic Publishers; 1995. p. 323-336.
98. Paulson DJ, Shug AL. Experimental evidence for the anti-ischemic effects of L-carnitine. In: De Jong JW, Ferrari R, editors. The carnitine system: a new therapeutical approach to cardiovascular diseases. Dordrecht (The Netherlands): Kluwer Academic Publishers; 1995. p..
99. Broderick TL, Quinney HA, Barker CC, et al. The beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993;87:972-98.
100. Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995;26:380-7.
101. Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995;26:1411-6.